Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Vaxcyte, Inc. has initiated a public offering of $1.0 billion in common stock and pre-funded warrants to support its vaccine development efforts against bacterial diseases [1] Company Overview - Vaxcyte is a clinical-stage vaccine innovation company focused on engineering high-fidelity vaccines to combat bacterial diseases [5] - The company is developing broad-spectrum conjugate and novel protein vaccines, including VAX-31, a Phase 3-ready 31-valent pneumococcal conjugate vaccine, and VAX-24, a 24-valent candidate currently in Phase 2 trials [5] - Vaxcyte's pipeline also includes candidates for Group A Strep infections, periodontal disease, and Shigella prevention [6] Offering Details - The public offering includes a 30-day option for underwriters to purchase an additional $150 million in shares [1] - The offering is subject to market conditions, and there is no guarantee on its completion or terms [1] - A shelf registration statement for the securities was filed with the SEC and became effective on May 24, 2024 [3] Management and Underwriters - BofA Securities, Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities, and Mizuho are acting as joint book-running managers for the offering [2]